Has Lawrence Rink, MD received payments from drug or device companies?

Yes. Drug and device makers reported $280,469 in general payments to Lawrence Rink, MD across 58 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lawrence Rink, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lawrence Rink, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lawrence Rink, MD

Cardiovascular Disease · Bloomington, INNPI 1740285519

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $280,000 of the $280,469 with a category attached, or 99.8%. Cook Incorporated accounts for 99.8% of it on its own, with 5 other manufacturers making up the rest. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$280,469in general payments, 2019–2025

Across 58 payments — averaging $4835.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Cook Incorporated$280K
Boehringer Ingelheim$177
Novartis$129
Cook Medical LLC$108
E.r. Squibb & Sons, L.L.C.$40
Boston Scientific$15

$32,210in research payments, 2019–2025

Across 9 payments — averaging $3578.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$15K
AstraZeneca$13K
Eisai Inc.$5K

What the payments were for

Consulting fees$280,000100%
Food & beverage$4290%
Education$400%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Cook Incorporated	28	$280,000
Boehringer Ingelheim	10	$177
Novartis	15	$129
Cook Medical LLC	2	$108
E.r. Squibb & Sons, L.L.C.	2	$40
Boston Scientific	1	$15

How this compares

$280,469 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana →

Medicare billing

Part B allowed, 2024

$19,476

Medicare patients

Services billed

206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	71	$94,485
EntrestoSacubitril/Valsartan	15	$28,459
XareltoRivaroxaban	20	$23,204
Praluent PenAlirocumab	19	$14,273
Ezetimibe	105	$3,106
Amiodarone Hcl	24	$1,267
Rosuvastatin Calcium	88	$1,175
Atorvastatin Calcium	124	$1,104
Celecoxib	14	$920
Metoprolol Succinate	71	$915
Carvedilol	70	$580
Warfarin Sodium	43	$546
Tamsulosin Hcl	21	$457
Pravastatin Sodium	17	$384
Amlodipine Besylate	43	$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
NovartisEntresto	$129	$28,45915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Bloomington

Joan CrawfordBloomington$77K
John MillerIndianapolis$354K
David KovacichIndianapolis$327K
Wai LeeElkhart$321K
Anas SafadiHobart$295K
Vijay RaoIndianapolis$247K
Steven SteinhublLafayette$247K
Atul ChughIndianapolis$242K
James TrippiIndianapolis$239K
Christopher HealyIndianapolis$209K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →